181 related articles for article (PubMed ID: 17133160)
41. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.
Sevigny JJ; Albert SM; McDermott MP; McArthur JC; Sacktor N; Conant K; Schifitto G; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Epstein LG; Marder K
Neurology; 2004 Dec; 63(11):2084-90. PubMed ID: 15596754
[TBL] [Abstract][Full Text] [Related]
42. The abacavir hypersensitivity reaction: a review.
Clay PG
Clin Ther; 2002 Oct; 24(10):1502-14. PubMed ID: 12462283
[TBL] [Abstract][Full Text] [Related]
43. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
Patel P; Bush T; Overton T; Baker J; Hammer J; Kojic E; Conley L; Henry K; Brooks JT;
Antivir Ther; 2012; 17(4):755-61. PubMed ID: 22301072
[TBL] [Abstract][Full Text] [Related]
44. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee.
Gibb DM; Newberry A; Klein N; de Rossi A; Grosch-Woerner I; Babiker A
Lancet; 2000 Apr; 355(9212):1331-2. PubMed ID: 10776748
[TBL] [Abstract][Full Text] [Related]
45. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex.
Brew BJ
AIDS; 2004 Jan; 18 Suppl 1():S75-8. PubMed ID: 15075501
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy.
Sei S; Stewart SK; Farley M; Mueller BU; Lane JR; Robb ML; Brouwers P; Pizzo PA
J Infect Dis; 1996 Dec; 174(6):1200-6. PubMed ID: 8940209
[TBL] [Abstract][Full Text] [Related]
47. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.
Palella FJ; Gange SJ; Benning L; Jacobson L; Kaplan RC; Landay AL; Tracy RP; Elion R
AIDS; 2010 Jul; 24(11):1657-65. PubMed ID: 20588104
[TBL] [Abstract][Full Text] [Related]
48. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy.
Satchell CS; O'Halloran JA; Cotter AG; Peace AJ; O'Connor EF; Tedesco AF; Feeney ER; Lambert JS; Sheehan GJ; Kenny D; Mallon PW
J Infect Dis; 2011 Oct; 204(8):1202-10. PubMed ID: 21917893
[TBL] [Abstract][Full Text] [Related]
49. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.
Calcagno A; Simiele M; Alberione MC; Bracchi M; Marinaro L; Ecclesia S; Di Perri G; D'Avolio A; Bonora S
Clin Infect Dis; 2015 Jan; 60(2):311-7. PubMed ID: 25281609
[TBL] [Abstract][Full Text] [Related]
50. Abacavir update.
Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366488
[TBL] [Abstract][Full Text] [Related]
51. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.
Margolis DM; Kewn S; Coull JJ; Ylisastigui L; Turner D; Wise H; Hossain MM; Lanier ER; Shaw LM; Back D
J Acquir Immune Defic Syndr; 2002 Sep; 31(1):45-9. PubMed ID: 12352149
[TBL] [Abstract][Full Text] [Related]
52. Use of abacavir in 30 HIV-infected children from Durban, South Africa: report from a pilot study.
Bobat R; Kindra G; Kiepiela P; Reddy S; Jeena PM; Adhikari M; Coovadia HM
Pediatr Infect Dis J; 2010 Sep; 29(9):890. PubMed ID: 20720476
[No Abstract] [Full Text] [Related]
53. Anti-HIV agents. Abacavir only once-daily.
TreatmentUpdate; 2003 Oct; 15(6):4. PubMed ID: 17216862
[No Abstract] [Full Text] [Related]
54. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.
Jullien V; Urien S; Chappuy H; Dimet J; Rey E; Pons G; Blanche S; Tréluyer JM
J Clin Pharmacol; 2005 Mar; 45(3):257-64. PubMed ID: 15703361
[TBL] [Abstract][Full Text] [Related]
55. [Risk factors for Abacavir-induced hypersensibility syndrome in the "real world"].
Chirouze C; Hustache-Mathieu L; Rougeot C; Drobacheff C; Gil H; Faller JP; Lebrun C; Estavoyer JM; Hénon T; Hoen B
Pathol Biol (Paris); 2004 Nov; 52(9):529-33. PubMed ID: 15531117
[TBL] [Abstract][Full Text] [Related]
56. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.
Frissen PH; de Vries J; Weigel HM; Brinkman K
AIDS; 2001 Jan; 15(2):289. PubMed ID: 11216946
[No Abstract] [Full Text] [Related]
57. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.
Capparelli EV; Letendre SL; Ellis RJ; Patel P; Holland D; McCutchan JA
Antimicrob Agents Chemother; 2005 Jun; 49(6):2504-6. PubMed ID: 15917556
[TBL] [Abstract][Full Text] [Related]
58. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
[TBL] [Abstract][Full Text] [Related]
59. Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS).
Gandhi RT; Tashima KT; Smeaton LM; Vu V; Ritz J; Andrade A; Eron JJ; Hogg E; Fichtenbaum CJ
J Infect Dis; 2020 Apr; 221(9):1407-1415. PubMed ID: 31135883
[TBL] [Abstract][Full Text] [Related]
60. An unusual abacavir reaction.
Fox J; Newton P; Daly R; Blume A; Marett B; Greene L; Winston A
AIDS; 2008 Jul; 22(12):1520-2. PubMed ID: 18614878
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
